(888) 352-RUSH for help arranging an appointment.
Faculty Rank: Professor
Medical or Graduate Education:
New Jersey Medical School
Massachusetts General Hospital - Psychiatry
Massachusetts General Hospital - Psychiatry
Post-traumatic stress disorder
Psychopharmacology integrated with medical management
Psychotropic medication management
Acute and long-term course and treatment of anxiety and traumatic stress disorders
Development of novel therapuetics for mood and anxiety disorders
Combined cognitive-behavioral and pharmacotherapy for anxiety disorders
Treatment refractory mood and anxiety disorders
Pathophysiology and treatment of substance abuse
Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.
Randomized controlled trial of mindfulness meditation for generalized anxiety disorder: effects on anxiety and stress reactivity. Hoge EA, Bui E, Marques L, Metcalf CA, Morris LK, Robinaugh DJ, Worthington JJ, Pollack MH, Simon NM. J Clin Psychiatry. 2013 2013 Mar 13. [Epub ahead of print] D-Cycloserine Enhancement of Fear Extinction is Specific to Successful Exposure Sessions: Evidence from the Treatment of Height Phobia. Smits JA, Rosenfield D, Otto MW, Powers MB, Hofmann SG, Telch MJ, Pollack MH, Tart CD. Biol Psychiatry. 2013 2013 Jan 16. doi:pii: S0006-3223(12)01094-3. 10.1016/j.biopsych.2012.12.009. [Epub ahead of print] Predictors of dropout from psychosocial treatment in opioid-dependent outpatients. McHugh RK, Murray HW, Hearon BA, Pratt EM, Pollack MH, Safren SA, Otto MW. Am J Addict. 2013 2013 Jan 22(1):18-22. doi: 10.1111/j.1521-0391.2013.00317.x. Augmentation of exposure therapy with post-session administration of d-cycloserine. Tart CD, Handelsman PR, Deboer LB, Rosenfield D, Pollack MH, Hofmann SG, Powers MB, Otto MW, Smits JA. J Psychiatr Res. 2013 2013 Feb 47(2):168-74. doi: 10.1016/j.jpsychires.2012.09.024. Epub 2012 Oct 23. Loving-Kindness Meditation practice associated with longer telomeres in women. Hoge EA, Chen MM, Orr E, Metcalf CA, Fischer LE, Pollack MH, Devivo I, Simon NM. Brain Behav Immun. 2013 2013 Apr 19. doi:pii: S0889-1591(13)00173-6. 10.1016/j.bbi.2013.04.005. [Epub ahead of print] d-Cycloserine as an Augmentation Strategy With Cognitive-Behavioral Therapy for Social Anxiety Disorder. Hofmann SG, Smits JA, Rosenfield D, Simon N, Otto MW, Meuret AE, Marques L, Fang A, Tart C, Pollack MH. Am J Psychiatry. 2013 2013 Apr 19. doi: 10.1176/appi.ajp.2013.12070974. [Epub ahead of print] Predicting Treatment Response in Social Anxiety Disorder From Functional Magnetic Resonance Imaging. Doehrmann O, Ghosh SS, Polli FE, Reynolds GO, Horn F, Keshavan A, Triantafyllou C, Saygin ZM, Whitfield-Gabrieli S, Hofmann SG, Pollack M, Gabrieli JD. Arch Gen Psychiatry. 2012 2012 Sep 3:1-11. doi: 10.1001/2013.jamapsychiatry.5. [Epub ahead of print] Plasma oxytocin immunoreactive products and response to trust in patients with social anxiety disorder. Hoge EA, Lawson EA, Metcalf CA, Keshaviah A, Zak PJ, Pollack MH, Simon NM. Depress Anxiety. 2012 2012 Nov 29(11):924-30. doi: 10.1002/da.21973. Epub 2012 Jul 17. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. Safren SA, O'Cleirigh CM, Bullis JR, Otto MW, Stein MD, Pollack MH. J Consult Clin Psychol. 2012 2012 Jun 80(3):404-15. doi: 10.1037/a0028208. Epub 2012 Apr 30. Anchoring the Panic Disorder Severity Scale. Keough ME, Porter E, Kredlow MA, Worthington JJ, Hoge EA, Pollack MH, Shear MK, Simon NM. Assessment. 2012 2012 Jun 19(2):257-9. doi: 10.1177/1073191112436668. Epub 2012 Feb 11. Sexual HIV risk behaviors in a treatment-refractory opioid-dependent sample. McHugh RK, Weitzman M, Safren SA, Murray HW, Pollack MH, Otto MW. J Psychoactive Drugs. 2012 2012 Jul-Aug 44(3):237-42. Avoidant personality disorder in individuals with generalized social anxiety disorder: what does it add? Marques L, Porter E, Keshaviah A, Pollack MH, Van Ameringen M, Stein MB, Simon NM. J Anxiety Disord. 2012 2012 Aug 26(6):665-72. doi: 10.1016/j.janxdis.2012.05.004. Epub 2012 May 27. Mood regulation and quality of life in social anxiety disorder: an examination of generalized expectancies for negative mood regulation. Sung SC, Porter E, Robinaugh DJ, Marks EH, Marques LM, Otto MW, Pollack MH, Simon NM. J Anxiety Disord. 2012 2012 Apr 26(3):435-41. doi: 10.1016/j.janxdis.2012.01.004. Epub 2012 Jan 16. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M, Harper L, Levy M, Rickels K, Pollack M. Psychother Psychosom. 2012 2012 81(2):87-97. doi: 10.1159/000332050. Epub 2012 Jan 25. Erratum in: Psychother Psychosom. 2012;81(4):261. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. Mischoulon D, Witte J, Levy M, Papakostas GI, Pet LR, Hsieh WH, Pencina MJ, Ward S, Pollack MH, Fava M. J Clin Psychiatry. 2011 Sep 20 Treatment change of somatic symptoms and cultural syndromes among Cambodian refugees with PTSD. Hinton DE, Kredlow MA, Bui E, Pollack MH, Hofmann SG. Depress Anxiety. 2011 Nov 7 doi: 10.1002/da.20905 The role of anxiety sensitivity in sleep disturbance in panic disorder. Hoge EA, Marques L, Wechsler RS, Lasky AK, Delong HR, Jacoby RJ, Worthington JJ, Pollack MH, Simon NM. J Anxiety Disord. 2011 May 25(4):536-8 Understanding the relationship of perceived social support to post-trauma cognitions and posttraumatic stress disorder. Robinaugh DJ, Marques L, Traeger LN, Marks EH, Sung SC, Gayle Beck J, Pollack MH, Simon NM. J Anxiety Disord. 2011 Jul 19 Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. Pollack MH, Hoge EA, Worthington JJ, Moshier SJ, Wechsler RS, Brandes M, Simon NM. J Clin Psychiatry. 2011 Jul 72(7):892-7 Effect of Acute Posttrauma Propranolol on PTSD Outcome and Physiological Responses During Script-Driven Imagery. Hoge EA, Worthington JJ, Nagurney JT, Chang Y, Kay EB, Feterowski CM, Katzman AR, Goetz JM, Rosasco ML, Lasko NB, Zusman RM, Pollack MH, Orr SP, Pitman RK. CNS Neurosci Ther. 2011 Jan 10 doi: 10.1111/j.1755-5949.2010.00227.x Culturally adapted CBT (CA-CBT) for Latino women with treatment-resistant PTSD: a pilot study comparing CA-CBT to applied muscle relaxation. Hinton DE, Hofmann SG, Rivera E, Otto MW, Pollack MH. Behav Res Ther. 2011 Apr 49(4):275-80 RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). Chandler GM, Iosifescu DV, Pollack MH, Targum SD, Fava M. CNS Neurosci Ther. 2010 Oct 16(5):322-5. doi: 10.1111/j.1755-5949.2009.00102.x. Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. Stein MB, Ravindran LN, Simon NM, Liebowitz MR, Khan A, Brawman-Mintzer O, Lydiard RB, Pollack MH. J Clin Psychiatry. 2010 May 71(5):627-31 Khyâl attacks: a key idiom of distress among traumatized Cambodia refugees. Hinton DE, Pich V, Marques L, Nickerson A, Pollack MH. Cult Med Psychiatry. 2010 Jun 34(2):244-78. Duloxetine for the treatment of generalized social anxiety disorder: a preliminary randomized trial of increased dose to optimize response. Simon NM, Worthington JJ, Moshier SJ, Marks EH, Hoge EA, Brandes M, Delong H, Pollack MH. CNS Spectr. 2010 Jul 15(7):367-73. Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, Hofmann SG, Eisenmenger K, Krystal JH, Pollack MH. Biol Psychiatry. 2010 Feb 15 67(4):365-70 Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: Further evaluation. Otto MW, McHugh RK, Simon NM, Farach FJ, Worthington JJ, Pollack MH. Behav Res Ther. 2010 Aug 48(8):720-7 Open-label support for duloxetine for the treatment of panic disorder. Simon NM, Kaufman RE, Hoge EA, Worthington JJ, Herlands NN, Owens ME, Pollack MH. CNS Neurosci Ther. 2009 Winter 15(1):19-23. A comparison of emotional approach coping (EAC) between individuals with anxiety disorders and nonanxious controls. Marques L, Kaufman RE, LeBeau RT, Moshier SJ, Otto MW, Pollack MH, Simon NM. CNS Neurosci Ther. 2009 Summer 15(2):100-6. Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial. Simon NM, Otto MW, Worthington JJ, Hoge EA, Thompson EH, Lebeau RT, Moshier SJ, Zalta AK, Pollack MH. J Clin Psychiatry. 2009 Nov 70(11):1563-70 Anger, PTSD, and the nuclear family: a study of Cambodian refugees. Hinton DE, Rasmussen A, Nou L, Pollack MH, Good MJ. Soc Sci Med. 2009 Nov 69(9):1387-94 Nightmares among Cambodian refugees: the breaching of concentric ontological security. Hinton DE, Hinton AL, Pich V, Loeum JR, Pollack MH. Cult Med Psychiatry. 2009 Jun 33(2):219-65. A PET study of tiagabine treatment implicates ventral medial prefrontal cortex in generalized social anxiety disorder. Evans KC, Simon NM, Dougherty DD, Hoge EA, Worthington JJ, Chow C, Kaufman RE, Gold AL, Fischman AJ, Pollack MH, Rauch SL. Neuropsychopharmacology. 2009 Jan 34(2):390-8 Anxiety disorder presentations in Asian populations: a review. Hinton DE, Park L, Hsia C, Hofmann S, Pollack MH. CNS Neurosci Ther. 2009 Fall 15(3):295-303 Introduction to the special issue: anxiety disorders in cross-cultural perspective. Hinton DE, Pollack MH. CNS Neurosci Ther. 2009 Fall 15(3):207-9. A model of the generation of ataque de nervios: the role of fear of negative affect and fear of arousal symptoms. Hinton DE, Lewis-Fernández R, Pollack MH. CNS Neurosci Ther. 2009 Fall 15(3):264-75. Mechanisms of efficacy of CBT for Cambodian refugees with PTSD: improvement in emotion regulation and orthostatic blood pressure response. Hinton DE, Hofmann SG, Pollack MH, Otto MW. CNS Neurosci Ther. 2009 Fall 15(3):255-63. Brain GABA levels in patients with bipolar disorder. Kaufman RE, Ostacher MJ, Marks EH, Simon NM, Sachs GS, Jensen JE, Renshaw PF, Pollack MH. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30 33(3):427-34 Broad spectrum of cytokine abnormalities in panic disorder and posttraumatic stress disorder. Hoge EA, Brandstetter K, Moshier S, Pollack MH, Wong KK, Simon NM. Depress Anxiety. 2009 26(5):447-55. Childhood maltreatment linked to greater symptom severity and poorer quality of life and function in social anxiety disorder. Simon NM, Herlands NN, Marks EH, Mancini C, Letamendi A, Li Z, Pollack MH, Van Ameringen M, Stein MB. Depress Anxiety. 2009 26(11):1027-32. Refractory generalized anxiety disorder. Pollack MH. J Clin Psychiatry. 2009 70 Suppl 2:32-8 Redefining affective disorders: relevance for drug development. Targum SD, Pollack MH, Fava M. CNS Neurosci Ther. 2008 Spring 14(1):2-9 Changing times at CNS Neuroscience & Therapeutics. Pollack MH. CNS Neurosci Ther. 2008 Spring 14(1):1 Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. Pollack MH, Endicott J, Liebowitz M, Russell J, Detke M, Spann M, Ball S, Swindle R. J Psychiatr Res. 2008 Oct 42(12):1042-9 Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. Pollack MH, Kornstein SG, Spann ME, Crits-Christoph P, Raskin J, Russell JM. J Psychiatr Res. 2008 Oct 42(14):1176-84 Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Simon NM, Connor KM, LeBeau RT, Hoge EA, Worthington JJ 3rd, Zhang W, Davidson JR, Pollack MH. Psychopharmacology (Berl). 2008 May 197(4):675-81 Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Pollack M, Kinrys G, Krystal A, McCall WV, Roth T, Schaefer K, Rubens R, Roach J, Huang H, Krishnan R. Arch Gen Psychiatry 2008 May 65(5):551-62. A detailed examination of cytokine abnormalities in Major Depressive Disorder. Simon NM, McNamara K, Chow CW, Maser RS, Papakostas GI, Pollack MH, Nierenberg AA, Fava M, Wong KK. Eur Neuropsychopharmacol. 2008 Mar 18(3):230-3 Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. Simon NM, Connor KM, Lang AJ, Rauch S, Krulewicz S, LeBeau RT, Davidson JR, Stein MB, Otto MW, Foa EB, Pollack MH. J Clin Psychiatry. 2008 Mar 69(3):400-5. Anxiety is associated with impulsivity in bipolar disorder. Taylor CT, Hirshfeld-Becker DR, Ostacher MJ, Chow CW, LeBeau RT, Pollack MH, Nierenberg AA, Simon NM. J Anxiety Disord. 2008 Jun 22(5):868-76 Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. Hoge EA, Worthington JJ 3rd, Kaufman RE, Delong HR, Pollack MH, Simon NM. CNS Spectr. 2008 Jun 13(6):522-7. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. Pollack MH, Tiller J, Xie F, Trivedi MH. J Clin Psychopharmacol. 2008 Jun 28(3):308-16. The 'multiplex model' of somatic symptoms: application to tinnitus among traumatized Cambodian refugees. Hinton DE, Hinton SD, Loeum RJ, Pich V, Pollack MH. Transcult Psychiatry. 2008 Jun 45(2):287-317. Oxytocin levels in social anxiety disorder. Hoge EA, Pollack MH, Kaufman RE, Zak PJ, Simon NM. CNS Neurosci Ther. 2008 Fall 14(3):165-70. Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies. Davidson J, Allgulander C, Pollack MH, Hartford J, Erickson JS, Russell JM, Perahia D, Wohlreich MM, Carlson J, Raskin J. Hum Psychopharmacol. 2008 Aug 23(6):519-26. High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: response to treatment with levetiracetam. Pollack MH, Jensen JE, Simon NM, Kaufman RE, Renshaw PF. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 1 32(3):739-43 A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders. George MS, Ward HE Jr, Ninan PT, Pollack M, Nahas Z, Anderson B, Kose S, Howland RH, Goodman WK, Ballenger JC. Brain Stimul 2008 Apr 1(2):112-21 Novel treatment approaches for refractory anxiety disorders. Pollack MH, Otto MW, Roy-Byrne PP, Coplan JD, Rothbaum BO, Simon NM, Gorman JM. Depress Anxiety. 2008 25(6):467-76. Ataque de nervios: relationship to anxiety sensitivity and dissociation predisposition. Hinton DE, Chong R, Pollack MH, Barlow DH, McNally RJ. Depress Anxiety. 2008 25(6):489-95. Examination of the decline in symptoms of anxiety and depression in generalized anxiety disorder: impact of anxiety sensitivity on response to pharmacotherapy. Olatunji BO, Feldman G, Smits JA, Christian KM, Zalta AK, Pollack MH, Simon NM. Depress Anxiety. 2008 25(2):167-71. The panic attack-posttraumatic stress disorder model: applicability to orthostatic panic among Cambodian refugees. Hinton DE, Hofmann SG, Pitman RK, Pollack MH, Barlow DH. Cogn Behav Ther. 2008 37(2):101-16. A functional MRI study of amygdala responses to angry schematic faces in social anxiety disorder. Evans KC, Wright CI, Wedig MM, Gold AL, Pollack MH, Rauch SL. Depress Anxiety. 2008 25(6):496-505.
To watch a brief video of Mark H. Pollack, MD, click the play button at the lower left corner of the video frame below.
(If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
We’re able to offer people with mood, anxiety, substance abuse difficulties a whole array of effective kinds of treatments: pharmacologic treatments, medications and different kinds of talking therapies — either specific talking therapies that help people deal with some of the symptoms associated with their difficulties, or more general more open-ended kinds of therapies that may help them understand how they got to where they are now, and what they can do in the future to get better.
There’s been a lot of stigma, especially in the past, associated with psychiatric disorders. As we learn more about these difficulties we realize that they’re just another type of illness or difficulty that people have in the same way they may have heart disease, or lung disease or GI [gastrointestinal] disease.
I think the important thing to realize is that there’s always hope, that we keep working with people until they’re doing better, and most of our patients do, in fact, experience a significant improvement in the quality of their life.